Liquidia stock broke out to a record high Monday after the company smashed first-quarter sales expectations on the back of its bread-and-butter drug, Yutrepia.
Yutrepia treats high pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, or PAH and PH-ILD
Both are forms of high blood pressure in the lungs. During the first three months of the year,… Related news This Drug Stock Nears A Buy Point, With Profit Set To Explode 4/27/2026 This drug stock is testing a moving average in a base. This biopharma name has a patented technology to administer… 4/27/2026 This drug stock is testing a moving average in a